Related Experiment Videos
Atrial fibrillation, anticoagulation, and stroke
J Morley1, R Marinchak, S J Rials
1Division of Cardiovascular Diseases, Lankenau Hospital and Medical Research Center, Wynnewood, Pennsylvania 19096, USA.
Insights
Atrial fibrillation increases stroke risk, especially with hypertension, age, prior TIA, or diabetes. Warfarin therapy significantly reduces stroke risk by 64% in these patients.
Area of Science:
- Cardiology
- Neurology
- Clinical Trials
Background:
- Atrial fibrillation (AF) is linked to rheumatic valvular disease and embolic stroke.
- Identifying high-risk AF patients for stroke prevention is crucial.
Purpose of the Study:
- To assess clinical trial data on stroke risk in atrial fibrillation patients.
- To evaluate the efficacy of anticoagulation therapy, specifically warfarin, in reducing stroke risk.
Main Methods:
- Analysis of 6 major clinical trials (AFASAK, BAATAF, SPINAF, SPAF, CAFA, EAFTA).
- Multivariate analysis to identify independent clinical risk factors for stroke in AF patients.
- Meta-analysis of warfarin therapy versus placebo.
Main Results:
- Hypertension, increasing age, previous transient ischemic attack (TIA), and diabetes mellitus are key stroke risk factors in AF.
- Patients with these risk factors face a 4% annual stroke risk without anticoagulation.
- Warfarin therapy demonstrated a 64% risk reduction for stroke compared to placebo.
- Higher risk of hemorrhagic complications with warfarin in patients over 75.
Conclusions:
- Warfarin therapy is effective in reducing stroke risk for AF patients with identified risk factors.
- Risk stratification using clinical features aids in targeted anticoagulation decisions.
- Caution is advised for warfarin use in elderly AF patients due to bleeding risks.
Abstract:
There is a demonstrated statistical association between atrial fibrillation, rheumatic valvular disease, and embolic stroke. This article assesses the results of 6 major clinical trials (AFASAK, BAATAF, SPINAF, SPAF [parts I and II], CAFA and EAFTA--see text for trial names). Multivariate analysis revealed 4 independent clinical features that identified patients with atrial fibrillation at an increased risk for stroke: hypertension, increasing age, previous transient ischemic attack, and diabetes mellitus. Without anticoagulation therapy, patients with any of these risk factors had a 4% annual risk of stroke. Patients with cardiac disorders such as congestive heart failure and coronary artery disease have a stroke rate 3 times higher than patients without any risk factors; patients with atrial fibrillation but no concomitant risk factors or structural heart disease seemed to have little concomitant risk for stroke. Meta-analysis revealed a 64% reduction of risk for stroke in patients treated with warfarin, as compared with placebo. The value of warfarin therapy in patients > 75 years old is less clear because of a high risk of hemorrhagic complications.